@article{e19468e1b8a94c268b8fa8c43a66c962,
title = "Genomic and clinical characterization of stromal infiltration markers in prostate cancer",
abstract = "Background: The progression of prostate cancer is a complex, multistep process that involves molecular alterations in cells of the tumor and the microenvironment, with associated interactions between the stroma and epithelium. Genomic expression analyses of stromal infiltration markers were performed to determine the significance thereof in prostate cancer. Methods: Genome-wide expression profiles of formalin-fixed, paraffin-embedded radical prostatectomy samples were evaluated from a prospective registry cohort (n = 5239) and 3 retrospective institutional cohorts (n = 1135). Two independent stromal gene expression signatures implied stromal infiltration. Cox proportional hazards regression defined the association between stromal infiltration expression and metastasis-free survival (MFS). Results: Stromal expression scores were correlated with stromal signature genes and with other key stromal markers (CAV1, VIM, and TAGLN), basal activity, and CD3 and CD4 immune biomarkers (r > 0.5 for all). The top decile of stromal expression was associated with high genomic risk scores (Decipher ≥ 0.6), high Cancer of the Prostate Risk Assessment–Postsurgical scores, Gleason 9 to 10 disease, and a higher risk for metastasis (hazard ratio, 2.35; 95% CI, 1.37-4.02; P =.001). A higher stromal infiltration score was also associated with decreased expression of DNA repair genes and higher radiation sensitivity genomic scores. Postoperative radiation therapy (RT) was associated with an MFS benefit for patients with high stromal scores, but not for patients with low stromal scores (Pinteraction =.02). Conclusions: Expression of stromal infiltration markers is correlated with prostate cancer aggressiveness/progression and may be predictive of a response to RT. Stromal infiltration markers should be studied and considered for incorporation into clinical prognostication and decision making.",
keywords = "Decipher, genomics, prostatic neoplasms, stromal infiltration, tumor microenvironment",
author = "Mahal, {Brandon A.} and Mohammed Alshalalfa and Zhao, {Shuang G.} and Himisha Beltran and Chen, {William S.} and Fallon Chipidza and Elai Davicioni and Karnes, {R. Jeffrey} and Ku, {Sheng Yu} and Lotan, {Tamara L.} and Vinayak Muralidhar and Rebbeck, {Timothy R.} and Schaeffer, {Edward M.} and Spratt, {Daniel E.} and Feng, {Felix Y.} and Nguyen, {Paul L.}",
note = "Funding Information: Mohammed Alshalalfa reports personal fees from GenomeDx outside the submitted work. Brandon Mahal reports grants from the Department of Defense, Prostate Cancer Foundation, and American Society for Radiation Oncology; and travel honoraria from Genzyme, the Exeter Group, and the Prostate Health Education Network outside the submitted work. Shuang G. Zhao reports nonfinancial support and other from GenomeDx Biosciences outside the submitted work; in addition, Zhao reports 3 patents pending to GenomeDx Biosciences. Elai Davicioni reports personal fees from GenomeDx (Decipher) outside the submitted work. R. Jeffrey Karnes reports royalties from GenomeDx outside the submitted work. Tamara L. Lotan reports grants from the Prostate Cancer Foundation outside the submitted work. Daniel E. Spratt reports grants from the Prostate Cancer Foundation and personal fees from Janssen, Blue Earth, and AstraZeneca outside the submitted work. Felix Y. Feng reports personal fees from Dendreon, EMD Serono, Janssen Oncology, Ferring, Sanofi, Bayer, Blue Earth Diagnostics, Celgene, Medivation/Astellas, and Clovis Oncology and ownership interests in PFS Genomics outside the submitted work; in addition, Feng has a patent issued (EP3047037 A4). Paul L. Nguyen reports the receipt of consulting fees from Ferring, Bayer, Janssen, Astellas, Dendreon, GenomeDx, Blue Earth Diagnostics, Cota, Boston Scientific, and Nanobiotix; grant funding from Janssen, Bayer, and Astellas; and equity in Augmenix. The other authors made no disclosures. Funding Information: Mohammed Alshalalfa reports personal fees from GenomeDx?outside the submitted work. Brandon?Mahal reports?grants from the Department of Defense, Prostate Cancer Foundation, and American Society for Radiation Oncology; and travel honoraria from Genzyme, the Exeter Group, and the Prostate Health Education Network outside the submitted work. Shuang G. Zhao reports nonfinancial support and other from GenomeDx Biosciences outside the submitted work; in addition, Zhao reports 3 patents pending to GenomeDx Biosciences. Elai Davicioni reports personal fees from GenomeDx (Decipher) outside the submitted work. R. Jeffrey Karnes reports royalties from GenomeDx outside the submitted work. Tamara L. Lotan reports grants from the Prostate Cancer Foundation outside the submitted work. Daniel E. Spratt reports grants from the Prostate Cancer Foundation and personal fees from Janssen, Blue Earth, and AstraZeneca outside the submitted work. Felix Y. Feng reports personal fees from Dendreon, EMD Serono, Janssen Oncology, Ferring, Sanofi, Bayer, Blue Earth Diagnostics, Celgene, Medivation/Astellas, and Clovis Oncology and ownership interests in PFS Genomics outside the submitted work; in addition, Feng has a patent issued (EP3047037 A4). Paul L. Nguyen reports the receipt of consulting fees from Ferring, Bayer, Janssen, Astellas, Dendreon, GenomeDx, Blue Earth Diagnostics, Cota, Boston Scientific,?and Nanobiotix; grant funding from Janssen, Bayer, and Astellas; and equity in Augmenix. The other authors made no disclosures. Brandon A. Mahal is funded by the Prostate Cancer Foundation/American Society for Radiation Oncology Award to End Prostate Cancer (grant support). Timothy R. Rebbeck has reported the receipt of grants from the National Institutes of Health. Paul L. Nguyen is funded by the Prostate Cancer Foundation (grant support). This work was also supported by the Wood Family Foundation, the Baker family, the Freedman family, Fitz's Cancer Warriors, David and Cynthia Chapin, the Frashure family, Hugh Simons in honor of Frank and Anne Simons, the Campbell family in honor of Joan Campbell, the Scott Forbes and Gina Ventre Fund, and a grant from an anonymous family foundation (grant support). Funding Information: Brandon A. Mahal is funded by the Prostate Cancer Foundation/American Society for Radiation Oncology Award to End Prostate Cancer (grant support). Timothy R. Rebbeck has reported the receipt of grants from the National Institutes of Health. Paul L. Nguyen is funded by the Prostate Cancer Foundation (grant support). This work was also supported by the Wood Family Foundation, the Baker family, the Freedman family, Fitz's Cancer Warriors, David and Cynthia Chapin, the Frashure family, Hugh Simons in honor of Frank and Anne Simons, the Campbell family in honor of Joan Campbell, the Scott Forbes and Gina Ventre Fund, and a grant from an anonymous family foundation (grant support). Publisher Copyright: {\textcopyright} 2020 American Cancer Society",
year = "2020",
month = apr,
day = "1",
doi = "10.1002/cncr.32688",
language = "English (US)",
volume = "126",
pages = "1407--1412",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",
}